IMRX
Immuneering·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 4
Consensus Rating "Strong Buy"
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
EPS Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMRX
Immuneering Corporation
A biopharmaceutical company that advance several products for cancer and other diseases
245 Main Street, Second Floor, Cambridge, MA 02142
--
Immuneering Corporation was incorporated in Delaware in 2008. The Company is a clinical-stage oncology company seeking to develop and commercialize generic RAS/RAF drugs for a broad population of cancer patients. The company's goal is to achieve this universal RAS/RAF activity through deep circulatory inhibition of the MAPK pathway, impacting cancer cells while preserving healthy cells. The company's inclusive approach distinguishes the company from narrowly targeted precision therapies, which are limited to tumor patients with specific mutations.
Company Financials
EPS
IMRX has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.39, beating expectations. The chart below visualizes how IMRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
